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Abstract This study provides evidence that treatment with pre-
clustered ephrin A5-Fc results in a substantial increase in
the stability of the p110Q PI-3 kinase associated with EphA8,
thereby enhancing PI-3 kinase activity and cell migration on a
¢bronectin substrate. In contrast, co-expression of a lipid ki-
nase-inactive p110Q mutant together with EphA8 inhibits li-
gand-stimulated PI-3 kinase activity and cell migration on a
¢bronectin substrate, suggesting that the mutant has a dominant
negative e¡ect against the endogenous p110Q PI-3 kinase.
Signi¢cantly, the tyrosine kinase activity of EphA8 is not im-
portant for either of these processes. Taken together, our results
demonstrate that the stimulation of cell migration on a ¢bro-
nectin substrate by the EphA8 receptor depends on the p110Q
PI-3 kinase but is independent of a tyrosine kinase activity.
) 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The Eph family comprises at least 14 di¡erent receptors and
nine ligands, all of which are widely expressed in the central
and peripheral nervous systems during development and in
the adult [1^3]. Individual members of the Eph family have
been implicated in axon guidance as well as other processes
such as cell migration, boundary formation through the re-
striction of cellular intermingling, and angiogenesis [4]. Nu-
merous reports indicate that members of the Eph family exert
their function by a repulsive mechanism. Little is known
about the Eph signaling mechanism that mediates repulsion,
although activation of rho and rho kinase has been implicated
in the collapse of growth cones in retinal ganglion axons [5,6].
More recently, an inhibition of Ras and Raf signaling has
been shown for the EphB2-mediated signal transduction path-
way that leads to axon collapse [7]. However, in certain cases
such as in the vomeronasal system, it appears that members of
the EphA family play an attractive rather than repulsive role
[8]. Identi¢cation of the signal transduction pathway that me-
diates this contradictory e¡ect is likely essential for under-
standing the mechanistic basis of repulsion versus attraction.
The signaling molecules involved in Eph receptor-mediated
cell adhesion could be important for analyzing these mecha-
nisms, but the interactions among these molecules are appar-
ently quite complex. For example, the EphB1-promoted at-
tachment of cells to ¢bronectin in a tyrosine-kinase-dependent
manner is an essential aspect of this signal transduction mech-
anism. Also, Nck or the low-molecular-weight protein tyro-
sine phosphatase is also implicated [9^11]. EphB2 was shown
to indirectly control integrin activity by inducing R-Ras tyro-
sine phosphorylation, possibly through the intermediary of
the Src homology (SH2) domain-containing Eph receptor
binding protein 1 (SHEP1) [12,13]. EphA2 was also reported
to regulate integrin function by causing the dephosphoryla-
tion of focal adhesion kinase (FAK) [14]. More recently,
EphA8 has been shown to enhance integrin activity by a
mechanism that requires the p110Q PI-3 kinase but which is
independent of tyrosine kinase activity [15]. Other studies
have also shown that the binding of EphA receptors to eph-
rin-A-expressing cells leads to L1-integrin-dependent upregu-
lation of the adhesiveness of ¢broblast cells and that Fyn or
another unidenti¢ed protein may play an important role in
this process [16,17]. However, it has not been determined
whether these signaling proteins are expressed and whether
they play a pivotal role in axonal behavior and in the migra-
tion of physiologically relevant neurons that express Eph re-
ceptors or ephrin ligands.
PI-3 kinases phosphorylate phosphatidylinositide lipids at
the D3 position of the inositol ring, producing lipid second
messengers that are critical in the transduction of a variety of
signals [18]. There are two distinct mechanisms by which re-
ceptors can trigger increases in PI-3 kinase activity and in the
level of 3-OH’ phosphoinositides. The ¢rst involves the inter-
action of p110-p85 heterodimeric PI-3 kinases with tyrosine-
phosphorylated receptors or their substrates, through the SH2
domains of the p85 adaptor subunits. The second involves
direct activation of the p110Q isotype through an interaction
with GK or GLQ subunits, which are released upon agonist
activation of receptors linked to G proteins [19^22]. All stud-
ies of the p110Q isotype have focused on pathways that are
triggered by G protein-coupled receptors. In this respect, the
recent ¢nding that p110Q biochemically links the EphA8 re-
ceptor tyrosine kinase to integrin activation suggests that re-
ceptor-triggered signaling mechanisms could be more diverse
than previously thought. More importantly, the signaling
mechanism that is triggered by the EphA8 receptor through
the p110Q PI-3 kinase does not require the EphA8 tyrosine
kinase function. Although PI-3 kinase enzymes have been in-
tensively studied with respect to the regulation of integrin
activity, few reports have addressed the role of the p110Q iso-
form [23^27]. Possibly related, G protein-coupled receptors
have been shown to induce actin rearrangement or cell migra-
tion through p110Q isoform [28]. The role of p110Q in cell
migration has been studied primarily in neutrophils of p110Q
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knock-out mice. For example, in p110Q 3/3 mice phagocyte
chemotaxis in response to fMet-Leu-Phe and C5a is reduced,
and T lymphocyte development and activation are impaired
[29]. However, the causal signaling components downstream
of p110Q in this process remain to be identi¢ed, although
proteins containing phosphoinositide-interacting PH domains
are good candidates.
It has been well documented that Eph receptors and their
ligands are involved in the repulsive migration of spinal and
branchial neural crest cells [30^32] and that integrin activation
correlates well with cell migration [33^35]. We have previously
demonstrated that the EphA8 receptor stimulates integrin ac-
tivity through the intermediation of the p110Q PI-3 kinase
isotype [15]. We therefore asked whether EphA8 activation
could promote cell migration and if so, whether p110Q plays
an essential role in this mechanism. In this report, we show
that the ligand-stimulated EphA8 receptor promotes the sta-
bilization of the p110Q protein through complex formation.
Concomitantly, Eph receptor-associated lipid kinase activity
is substantially elevated, and the ability of cells to migrate on
¢bronectin is also enhanced. In addition, the stimulation of
cell migration depends on the lipid kinase activity of the p110Q
PI-3 kinase. These data suggest a signaling pathway that be-
gins with activation of the EphA8 receptor and culminates in
cell migration, one that sequentially involves p110Q PI-3 ki-
nase and integrin activation.
2. Materials and methods
2.1. Cell culture and transfection
HEK 293 cells were cultured in alpha-MEM (Sigma) containing
10% heat-inactivated fetal bovine serum (BioWhittaker). Transient
transfections were carried out using LipofectAMINE (Life Technolo-
gies, Inc.) according to the manufacturer’s instructions. For treatment
with preclustered ephrin A5-Fc proteins, puri¢ed ephrin A5-Fc (5 Wg/
ml) [36] was aggregated using anti-human Fc (Jackson Immunore-
search) for 30 min on ice and stimulations were for 30 min at 37‡C.
2.2. Expression vectors
The murine wild-type and kinase-inactive (K666M) EphA8 cDNA
tagged with the nine-amino-acid HA epitope (YPYDVPDYA) at its
COOH termini have been described elsewhere [15]. The murine wild-
type p110Q cDNA tagged with the eight-amino-acid FLAG epitope
(DYKDDDDK) at its COOH terminus has been described elsewhere
[15], together with its variants, including the lipid kinase-inactive
K833R and the membrane-targeted Myr-p110Q.
2.3. Immunoprecipitation, Western blotting and PI-3 kinase assay
Immunoprecipitation and Western blot analysis were performed as
previously described [37]. PI-3 kinase activity was measured as pre-
viously described with some modi¢cations [38]. Brie£y, proteins were
immunoprecipitated by incubating cell extracts with an anti-HA anti-
body and protein A-Sepharose. The Sepharose beads were washed
three times with HNTG bu¡er, once with 1% Nonidet P-40 in phos-
phate-bu¡ered saline (PBS), once with 100 mM Tris^HCl (pH 7.5)
containing 500 mM LiCl and once with 50 mM Tris^HCl bu¡er (pH
7.2) containing 150 mM NaCl. After the last wash, the beads were
resuspended in kinase bu¡er (20 mM HEPES, pH 7.2, 50 mM NaCl
and 1 mM EGTA) containing 4 Wg phosphatidylinositol (PI, Sigma),
10 WM ATP, 5 mM MnCl2, and 10 WCi [Q-32P]ATP and incubated for
20 min at 30‡C. The reaction was stopped by the addition of 100 Wl
1 N HCl and 200 Wl of a 1:1 mixture of chloroform and methanol.
The lipids were extracted and resolved on potassium oxalate-pre-
treated thin layer chromatography (TLC) plates (EM Science) with
35 ml 2N acetic acid and 65 ml 1-propanol as the mobile phase. Dried
plates were exposed to Kodak X-ray ¢lm for autoradiography.
2.4. Cell migration assay
Cell migration assays were performed using modi¢ed Boyden cham-
bers (tissue culture treated, 6.5 mm diameter, 10 Wm thickness, 8 Wm
pores, Transwell Costar Corp., Cambridge, MA, USA) containing a
polycarbonate membrane [39,40]. The underside of the upper chamber
membrane was coated with 10 Wg/ml ¢bronectin for 2 h at 37‡C,
rinsed once with PBS, and placed into the lower chamber in 500 Wl
tissue culture medium containing 10 Wg/ml ¢bronectin. Cells were
removed from culture dishes by brief trypsinization, washed once
with PBS and resuspended in culture medium. Fifty thousand cells
were added to the top of each migration chamber and allowed to
migrate to the underside of the top chamber for 2 h. Non-migratory
cells on the upper membrane surface were removed with a cotton
swab, and migratory cells attached to the bottom surface of the mem-
brane were stained with 0.1% crystal violet in 0.1 M borate, pH 9.0,
and 2% ethanol for 20 min at room temperature. The migratory cells
on each membrane were counted with an inverted microscope. Each
determination represents the average of three individual wells, and
error bars represent S.E.
2.5. Antibodies
The polyclonal rabbit antibody speci¢c for the juxtamembrane do-
main of EphA8 was described previously [37]. Polyclonal rabbit anti-
HA antibody was obtained from Zymed. Monoclonal mouse anti-
FLAG antibody was from Sigma. The HRP-conjugated secondary
antibodies were from Amersham Pharmacia Biotech.
3. Results
3.1. The stability of p110Q complexed with wild-type EphA8 is
increased by stimulation with ephrin A5
We have previously shown that the EphA8 receptor asso-
ciates with the p110Q PI-3 kinase and that lipid kinase activity
plays an essential role in the EphA8-stimulated adhesion of
cells to ¢bronectin [15]. These results led us to postulate that
activation of the EphA8 receptor upon stimulation by ephrin
A5 may promote cell migration on ¢bronectin by increasing
the lipid kinase activity of the p110Q protein. To test this
experimentally, we created murine p110Q PI-3 kinase cDNA
variants that encode the NH2-terminal myristoylation motif
from c-Src [myr-p110Q] [41,42], which is a membrane local-
ization signal, or that are mutated for a residue predicted to
be required for binding ATP [Lys-833 to Arg; p110Q-K833R]
or both [myr-p110Q-K833R] [21]. To assess the ability of these
p110Q PI-3 kinase variants to form a stable complex with the
EphA8 receptor under conditions of ephrin A5 stimulation,
we transiently co-expressed wild-type EphA8 with the p110Q
PI-3 kinase variants in HEK293 cells. The transfected cells
were stimulated with preclustered ephrin A5-Fc soluble ligand
for 30 min or left untreated, and cell lysates were prepared.
Ten percent of the whole cell lysate was directly assayed using
the anti-FLAG antibody as a probe, which detects the murine
p110Q PI-3 kinase tagged with the FLAG epitope at the car-
boxyl terminus (Fig. 1B). Interestingly, the steady state level
of each p110Q variant, and of wild-type p110Q, was signi¢-
cantly higher in cells stimulated with ephrin A5 than in un-
stimulated cells (Fig. 1B, lanes 3, 5, 7 and 9). In the absence of
EphA8, no increase in the level of p110Q protein in response
to treatment with ephrin A5 was observed (data not shown).
It also appeared that the level of expression of each of the
variant p110Q proteins di¡ered. For example, the membrane-
targeted wild-type p110Q protein was consistently expressed at
the highest level (Fig. 1B, lanes 5 and 6). To exclude the
possibility that the di¡erent levels of p110Q are due to di¡er-
ences in transfection e⁄ciency, another 10% of each whole cell
lysate preparation was analyzed by immunoblotting using an
anti-EphA8 antibody as a probe. As shown in Fig. 1C, the
levels of expression of the EphA8 receptor were not signi¢-
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cantly altered by ephrin A5 stimulation nor did they correlate
with the levels of expression of the individual p110Q variants.
Together, these results suggest that the level of expression of
each p110Q variant is speci¢cally due to its respective altera-
tion. In addition, our results suggest that stimulation by eph-
rin A5 stabilizes both wild-type and variant p110Q proteins,
possibly by promoting stable complex formation with the
EphA8 receptor.
To examine the ability of each of the p110Q variants to
associate with the activated wild-type EphA8 receptor in our
co-transfection system, we carried out co-immunoprecipita-
tion experiments using anti-HA antibody to harvest protein
complexes containing the EphA8 protein tagged with the HA
epitope. The anti-HA immunocomplexes were subjected to
stringent washing conditions and then to Western blot analy-
sis using the anti-FLAG antibody as a probe. As shown in
Fig. 1A, the level of each of the p110Q variants associated with
EphA8 was substantially higher in cells stimulated by ephrin
A5 (see lanes 3, 5, 7 and 9). Wild-type p110Q, p110Q-K833R
mutant, and myr-p110Q-K833R mutant were associated with
EphA8 up to approximately 2.5-fold higher, whereas myr-
p110Q protein was up to ¢ve-fold higher. A time course study
with preclustered ephrin A5-Fc revealed that the steady state
level of p110Q PI-3 kinase increased within 5^30 min of ligand
stimulation (data not shown). The same immunoprecipitates
were then assayed for their ability to phosphorylate PI in vitro
(Fig. 1D). In cells expressing EphA8 with a vector control,
PI-3 kinase activity, as indicated by the appearance of PI(3)P,
was reproducibly increased by ephrin A5 stimulation (Fig.
1D, lane 1). This increased activity can be explained by our
previous report that preclustered ephrin A5-Fc results in a
substantial increase in the stability of the endogenous p110Q
PI-3 kinase associated with EphA8. As expected from the
observation that the association of p110Q protein with
EphA8 is stabilized by ephrin A5 stimulation, PI-3 kinase
activity was high in response to ephrin A5 stimulation in cells
expressing EphA8 with either the wild-type p110Q (2.5-fold
Fig. 1. The p110Q PI-3 kinase associates with the wild-type EphA8
receptor. A: Wild-type EphA8-HA construct and each of the indi-
vidual p110Q cDNA variants were co-transfected into HEK293 cells
in lanes 3^10, whereas pcDNA3 was transfected as a control in
lanes 1 and 2. Forty-eight hour posttransfection, the cells were
treated (+) with preclustered ephrin A5-Fc for 30 min at 37‡C or
were untreated (3). Proteins from cell lysates were immunoprecipi-
tated with anti-HA antibody and then analyzed by immunoblotting
with anti-FLAG antibody as a probe. B: 10% of the whole cell ly-
sates (approximately 20 Wg) described above were directly analyzed
by immunoblotting with anti-FLAG antibody. C: 10% of the whole
cell lysates (approximately 20 Wg) described above were analyzed by
immunoblotting with anti-EphA8 antibody. D: Proteins from cell
lysates were immunoprecipitated with anti-HA antibody and then
incubated with 4 Wg PI and 10 WCi [Q-32P]ATP for 10 min, and the
reaction was analyzed by TLC followed by autoradiography.
Fig. 2. The p110Q protein associates with the kinase-inactive EphA8
receptor. Experiments were performed essentially as described in the
legend to Fig. 1, except that the kinase-inactive EphA8-K666M mu-
tant was used instead of the wild-type EphA8. A: Proteins from cell
lysates were immunoprecipitated with anti-HA antibody and then
analyzed by immunoblotting with anti-FLAG antibody as a probe.
B: 10% of the whole cell lysates (approximately 20 Wg) were directly
analyzed by immunoblotting with anti-FLAG antibody. C: 10% of
the whole cell lysates (approximately 20 Wg) were analyzed by im-
munoblotting with anti-EphA8 antibody. D: Proteins from cell ly-
sates were immunoprecipitated with anti-HA antibody, and PI-3 ki-
nase activity was measured as described in the legend to the
previous ¢gure.
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increase) or the membrane-targeted p110Q PI-3 kinase (four-
fold increase) (Fig. 1D, lanes 3 and 5). In contrast, the pres-
ence of the lipid kinase-inactive K833R mutants strongly in-
hibited PI-3 kinase activity stimulated by ephrin A5 regardless
of the membrane localization signal (Fig. 1D, lanes 7 and 9).
Taken together, these results reveal that treatment with ephrin
A5 rapidly enhances the stability of the p110Q protein com-
plexed with the EphA8 receptor, thereby promoting its lipid
kinase activity.
3.2. The stability of p110Q complexed with kinase-inactive
EphA8 is also increased by ephrin A5 stimulation
It was previously shown that the association of the p110Q
PI-3 kinase with EphA8 does not require the tyrosine kinase
activity of EphA8 [15]. To further assess whether the expres-
sion of the kinase-inactive EphA8 a¡ects the stability and
activity of the p110Q variants, we carried out identical experi-
ments except with the kinase-inactive K666M EphA8 mutant,
which contains Met in place of Lys 666, the putative ATP
binding residue. In co-transfected cells, the level of expression
of each of the p110Q variants was elevated by ephrin A5 stim-
ulation (Fig. 2B, lanes 3, 5, 7 and 9), whereas the expression
of the kinase-inactive EphA8 receptor was not signi¢cantly
altered by ephrin A5 stimulation or by the p110Q variant
(Fig. 2C). In addition, ephrin A5 stimulation caused an in-
crease in the steady state level and lipid kinase activity of both
the wild-type and membrane-targeted p110Q associated with
the kinase-inactive EphA8 (Fig. 2A,D, lanes 3 and 5). In
contrast, by tightly binding to the EphA8 receptor, the lipid
kinase-inactive p110Q mutant e⁄ciently blocked PI-3 kinase
activity stimulated by ephrin A5 (Fig. 2A,D, lanes 7 and 9).
Taken together, these ¢ndings are consistent with our pre-
vious result that the mechanism by which ephrin A5 promotes
the stable association of EphA8 and p110Q PI-3 kinase is in-
dependent of the EphA8 auto-kinase activity.
3.3. The lipid kinase activity of p110Q is essential for
cell migration promoted by the ligand-stimulated
EphA8 receptor
To determine whether the stability of the p110Q PI-3 kinase
complexed with Eph receptor correlates with its ability to
promote cell migration, transiently co-transfected cells were
analyzed by a modi¢ed Boyden chamber assay [39,40] using
¢bronectin as an attractant. In the absence of exogenous
p110Q, cells expressing either the wild-type EphA8 or kinase-
inactive EphA8 receptor exhibited an increased level of migra-
tion in response to ephrin A5 stimulation, as compared with
unstimulated cells (Fig. 3A,B, second bar of each panel). Like-
wise, the co-expression of either wild-type or membrane-tar-
geted p110Q with the EphA8 receptor markedly promoted cell
migration in response to ephrin A5 stimulation (Fig. 3A,B,
fourth and sixth bars of each panel). These e¡ects were inde-
pendent of EphA8 kinase activity and were not observed in
the absence of EphA8 expression (data not shown). In addi-
tion, the stimulation of cell migration correlated well with the
quantitative level and in vitro lipid kinase activity of the p110Q
PI-3 kinase associated with the EphA8 receptor (see Figs. 1
and 2, panels A and D, lanes 3 and 5). Interestingly, the
membrane-targeted p110Q PI-3 kinase enhanced cell migration
even without ephrin A5 stimulation, as compared with the
wild-type p110Q (Fig. 3A,B, ¢fth bar of each panel), and the
extent of cell migration was independent of the amount of
protein associated with EphA8. This result suggests that the
membrane localization of the p110Q PI-3 kinase has complex
consequences for cell migration. As shown in Figs. 1 and 2,
lipid kinase-inactive p110Q protein forms a tight complex with
the EphA8 receptor in response to ephrin A5 stimulation,
thereby inhibiting the endogenous p110Q protein in a domi-
nant negative manner. Consistent with these results, expres-
sion of K833R or myr-K833R mutant p110Q proteins e⁄-
ciently blocked ephrin A5-stimulated cell migration (Fig.
Fig. 3. A p110Q PI-3 kinase is required for cell migration induced by EphA8 expression and ephrin A5 stimulation. Cells were allowed to mi-
grate for 2 h on a ¢bronectin substrate after exposure to preclustered ephrin A5-Fc fusion protein for 30 min. Migration studies were per-
formed using Transwell migration chambers coated with ¢bronectin as described in Section 2. A: Wild-type EphA8 and the p110Q cDNA var-
iants were co-transfected into HEK293 cells. Forty-eight hour posttransfection, the cells were treated with preclustered ephrin A5-Fc for 30 min
at 37‡C or were untreated. Cells were brie£y treated with trypsin and subjected to cell migration assays. B: Experiments were performed essen-
tially as described in panel A, except that the kinase-inactive K666M EphA8 mutant was used instead of the wild-type EphA8 cDNA. The re-
sults represent the meanUS.E. of three independent experiments. In each experiment, four random ¢elds per well were scored.
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3A,B, eighth and tenth bars of each panel). Together, these
results demonstrate that the lipid kinase activity of the p110Q
PI-3 kinase is required for the ephrin A5-stimulated migration
of cells on ¢bronectin and that this signal transduction path-
way does not require the tyrosine kinase activity of the EphA8
receptor.
4. Discussion
Previous studies of p110Q PI-3 kinase isotypes have focused
on the heterotrimeric G protein-linked receptor signaling
mechanism by which the K or LQ subunit or both directly
modulate the activity of p110Q. [19^22]. Interestingly, our re-
cent studies revealed that the p110Q PI-3 kinase plays an es-
sential role in the EphA8-promoted cell adhesion to ¢bronec-
tin [15]. In the present study, we further showed that the
p110Q PI-3 kinase also plays a crucial role in the EphA8-
stimulated migration of cells on ¢bronectin. Taken together,
the above ¢ndings delineate a pathway, leading from activa-
tion of the EphA8 receptor to an increase in cell migration,
that sequentially involves EphA8, p110Q and integrin. In this
signal transduction mechanism, the p110Q-EphA8 complex is
stabilized, and thus possesses higher lipid kinase activity,
when stimulated by ephrin A5. Strikingly, the tyrosine kinase
function of the EphA8 receptor is not involved in this signal
transduction mechanism. These observations raise several im-
portant issues, including (i) the mechanism by which the
EphA8 receptor stabilizes p110Q, (ii) the mechanism by which
p110Q stimulates cell migration, and (iii) the physiological
relevance of the p110Q protein in the migration of neuronal
cells expressing EphA8.
The ¢rst issue concerns how ephrin A5 stabilizes the p110Q
protein^EphA8 receptor complex. We previously showed that
the stable association of EphA8 and p110Q involves the juxta-
membrane segment of EphA8 and that the level of expression
of EphA8 does not a¡ect p110Q mRNA levels [15]. The jux-
tamembrane region may be masked when the EphA8 extra-
cellular domain is unbound by ligand but may be exposed to
p110Q upon ligand binding. The multimeric form of the
EphA8 receptor, which is induced by ephrin ligand binding,
may protect the tightly associated p110Q PI-3 kinase from
degradation. Preaggregation of ephrin A5-Fc was required
for observing both p110Q PI-3 kinase stabilization and the
cell migration e¡ect, suggesting that only superaggregation
of EphA8 plays an essential role in p110Q stability (data not
shown). In this protein complex, lipid kinase activity may
partially contribute to the stability of p110Q, as manifested
by the lower level of expression of the K833R mutant (Figs.
1 and 2, panels A and B, lanes 8 and 10). In our previous
report, we claimed that kinase-inactive p110Q does not asso-
ciate with EphA8. This misleading conclusion most likely re-
sults from the lower sensitivity of the FLAG antibody used
for p110Q immunoprecipitation and the relatively low expres-
sion level of kinase-inactive p110Q. In its active conformation,
the p110Q lipid kinase may more readily form a stable com-
plex with EphA8, although this conformation is not abso-
lutely required for complex formation. The p101 regulatory
subunit may play an important role in the heterotrimeric G
protein-linked receptor signaling pathway that leads to the
activation of p110Q [43,44]. However, we observed that co-
expression of p101 together with p110Q has no e¡ect on
EphA8-stimulated cell migration (data not shown) or on
p110Q stability, suggesting that p101 is not required for the
EphA8-mediated modulation of p110Q PI-3 kinase activity.
The next question concerns the mechanism by which p110Q
promotes cell migration in response to stimulation by the
ephrin A5 ligand. Our studies suggest a role for phosphoino-
sitides in the inside-out signaling mechanism employed by
EphA8 in integrin activation [15]. The production of phos-
phoinositides in response to ephrin A5 stimulation is crucial
for promoting cell migration because treatment with pharma-
cologic inhibitors of PI-3 kinases (such as wortmannin or
LY294002) (data not shown) or co-expression of a catalyti-
cally inactive p110Q variant have inhibitory e¡ects on cell
migration enhanced by ephrin A5. Phosphoinositides may
act as second messengers by binding and modulating PH-do-
main-containing proteins such as Vav. Indeed, Vav, the Rac
GEF, has been implicated as an important mediator of a
signal transduction pathway leading from activation of the
chemoattractant formyl peptide receptor to cytoskeletal reor-
ganization, through the intermediation of p110Q PI-3 kinase
and Rac [28]. However, we have not observed dramatic
changes in actin polymerization in response to ephrin A5
stimulation (data not shown). Signi¢cant changes in the activ-
ity of Rho, Rac or the Cdc42 small GTP binding protein also
have have not been detected (data not shown). These results
suggest that the EphA8 receptor signals the p110Q PI-3 kinase
in a manner di¡erent from the stimulation of G protein-
coupled receptors. Although it remains to be determined
whether the activated EphA8 receptor can mediate cell migra-
tion through other PH-domain proteins, active phospholipid
products may also directly promote integrin conformational
changes, leading to an increase in cell migration. FAK has
also been implicated in integrin-mediated cell migration
[34,45], suggesting that it may be involved in EphA8-stimu-
lated cell migration. However, ephrin A5 does not induce
signi¢cant changes in FAK tyrosine phosphorylation under
conditions that promote cell migration (data not shown). Fur-
thermore, co-expression of the dominant negative FRNK
[40,46^48], an N-terminally truncated form of FAK, does
not inhibit EphA8-stimulated cell migration (data not shown),
suggesting that FAK and EphA8 mediate cell migration by
independent and parallel mechanisms. This may explain why
the dominant negative forms of p110Q do not further inhibit
the basal level of cell migration, which could be mediated by
other signaling proteins such as FAK.
A ¢nal issue is the biological and physiological relevance of
EphA8-stimulated p110Q for cell migration in vivo. Eph re-
ceptors are well documented in guiding the migration of spi-
nal or branchial neural crest cells, and several reports have
shown that ephrin ligands induce the repulsive migration of
neural crest cells [30^32]. In addition, cell migration was also
stimulated when cells were plated for 30 min on substrate-
immobilized ephrin A5-Fc protein, con¢rming the physiolog-
ical importance of the results obtained with preaggregated
ephrin A5-Fc ligand (data not shown). We also observed
that under conditions that promote cell migration, the coating
of ephrin A5 ligands, together with ¢bronectin, on Transwell
membranes e⁄ciently prevents cells from migrating towards
the bottom well (data not shown). These results suggest that
the activation of Eph receptors by ephrin ligand stimulates
cell migration along the extracellular matrix but not toward
the ligand-expressing region. In this mechanism, the p110Q PI-3
kinase may represent an important transducer in a pathway
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leading from Eph receptor activation to cell migration. We
also observed that the EphA4 receptor associates with p110Q
irrespective of its tyrosine kinase activity, suggesting that the
integrin activation property of p110Q is shared by other mem-
bers of the EphA family. The EphA8 gene is expressed only in
a subpopulation of midbrain neurons during murine embry-
onic development, and it has been suggested that the EphA8
receptor plays an important role in axonal path¢nding in a
subset of tectal commissural axons [49]. We could detect the
p110Q mRNA in tectal neurons by RT-PCR (reverse tran-
scription-polymerase chain reaction) but not in whole mount
embryos by in situ RNA hybridization (data not shown). This
observation suggests that the p110Q protein is present at low
levels or is unstable and that it may be increased by stimula-
tion with ephrin ligand. A test of this hypothesis would re-
quire a sensitive antibody against the murine p110Q PI-3 ki-
nase, which is under development in our laboratory. In
addition, to elucidate the biological relevance of our current
¢ndings, we have initiated studies of the p110Q variants ex-
pressed under the control of the EphA8 promoter in trans-
genic mice.
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